Nucala Insurance Denied? How to Appeal Your Mepolizumab Denial

Nucala (mepolizumab) is an anti-IL-5 biologic approved for severe eosinophilic asthma, eosinophilic granulomatosis with polyangiitis (EGPA), and hypereosinophilic syndrome (HES). It has reduced asthma exacerbations significantly in clinical trials and is a guideline-recommended treatment option. Yet insurance denials are common. Here's how to mount an effective appeal.

What Nucala Treats and Why Patients Need It

Nucala targets IL-5, the key cytokine responsible for the growth, activation, and survival of eosinophils. By blocking IL-5 signaling, mepolizumab substantially reduces circulating and tissue eosinophils.

FDA-approved indications include:

• Severe eosinophilic asthma in adults and pediatric patients age 6 and older
• Eosinophilic granulomatosis with polyangiitis (EGPA) in adults — the first biologic approved for this rare vasculitis
• Hypereosinophilic syndrome (HES) in adults without an identifiable cause — also the first approved therapy

In the MENSA and DREAM asthma trials, Nucala reduced severe exacerbation rates by 47–53% compared to placebo. For EGPA patients, Nucala achieved remission in significantly more patients and allowed dramatic reductions in oral corticosteroid use.

For patients with EGPA or HES in particular, Nucala may be the only approved biologic treatment option — making denial particularly unjustifiable.

Common Denial Reasons for Nucala

Blood eosinophil count below threshold: Most PA criteria require eosinophils ≥150 cells/µL (or ≥300 for some plans) for asthma coverage. If not documented with recent CBC, the PA is denied.

Severity not documented: Plans require evidence of at least two asthma exacerbations in the past 12 months or OCS dependence. Missing documentation of exacerbation history is a common reason for automatic denial.

Preferred biologic required first: Some plans prefer Fasenra (benralizumab) or Dupixent (dupilumab) over Nucala, especially for patients with very high eosinophil counts where newer agents may be preferred.

EGPA or HES indication not covered: Some plans don't separately list EGPA or HES in their asthma biologic coverage criteria, creating a formulary gap for patients with these rarer diagnoses.

Step therapy not completed: Plans may require additional steps in conventional asthma therapy before any biologic is approved.

Step-by-Step: How to Appeal a Nucala Denial

Step 1: Identify the denial reason precisely. The appeal for EGPA or HES is very different from a standard eosinophilic asthma appeal.

Step 2: Pull current eosinophil count and longitudinal eosinophil data. For EGPA and HES, documenting persistently elevated eosinophils over time is important for establishing diagnosis and severity.

Step 3: Have your specialist write a detailed Letter of Medical Necessity. For EGPA, a rheumatologist or pulmonologist should write the LMN. For HES, a hematologist or immunologist. For asthma, a pulmonologist or allergist.

Step 4: Compile exacerbation and treatment history. Document every relevant prior treatment — for asthma: ICS/LABA, OCS use. For EGPA: prior immunosuppressants (cyclophosphamide, azathioprine, methotrexate). For HES: prior steroid therapy and cytoreductive treatments.

Step 5: Submit the internal appeal with complete documentation and request peer-to-peer review.

Step 6: File an external appeal if the internal appeal fails. For EGPA and HES, note that Nucala is the only FDA-approved biologic for these conditions.

What to Include in Your Nucala Appeal Letter

• Policy number, member ID, and claim reference
• Specific indication: eosinophilic asthma, EGPA, or HES
• Most recent blood eosinophil count with date
• For asthma: exacerbation history, OCS use, current medications
• For EGPA: EGPA diagnosis documentation, prior immunosuppressant history, disease activity measures
• For HES: eosinophil levels over time, organ involvement documentation, prior treatments
• Letter of Medical Necessity from specialist
• Clinical trial citations: MENSA trial for asthma, MIRRA trial for EGPA
• FDA approval citations for all applicable indications
• Statement that Nucala is the only FDA-approved biologic for EGPA and HES (if applicable)
• Request for peer-to-peer review

Success Tips for Nucala Appeals

For EGPA and HES, the "only approved biologic" argument is powerful. Mepolizumab is the only FDA-approved biologic for eosinophilic granulomatosis with polyangiitis and hypereosinophilic syndrome. Denying the only approved treatment for a rare disease has a very different ethical and legal character than denying a preference among multiple options.

Show eosinophil data over time. Single-point eosinophil counts can be misleading (eosinophils fluctuate). Providing serial values — especially ones showing persistently elevated levels — makes the clinical case more compelling.

Document steroid burden for OCS-dependent patients. Long-term OCS use causes cumulative damage: osteoporosis, cataracts, adrenal suppression, metabolic syndrome. Demonstrating that the patient has been on chronic OCS and Nucala can eliminate or reduce that burden is a powerful cost-benefit argument.

Seek EGPA or HES specialist support. These are rare diseases. A rheumatologist or hematologist who specializes in these conditions can provide expert testimony that carries substantial weight in a peer-to-peer review.

Fight Back With ClaimBack

Nucala is an FDA-approved treatment that your specialist has determined is necessary — sometimes the only available option. An insurance denial shouldn't stand between you and effective therapy. ClaimBack can help you fight back.

Start your Nucala appeal at ClaimBack

Related Reading

• How to Write an Insurance Appeal Letter
• What Is Medical Necessity?
• Common Reasons Insurance Claims Are Denied